The Food and Drug Administration in recent months has approved a small number of drugs quite quickly under a new expedited ...
Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the treatment of ...
HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) and Innovent Biologics, Inc. (“Innovent”, HKEX:1801) today jointly announce that the New Drug Application (NDA) for the combination of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results